Alternate links: Google News | Twitter
No, this isn't the plot of some kingpin drama on Starz.
Rather, it's the conclusion of new reporting from The Wall Street Journal on how a business tied to Donald Trump Jr. stands to benefit from his father's newly announced plan to launch a Trump-branded pharmaceutical market funded by the government.